Logo
x

Search

Subscribe Now

rituximab

Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin's Lymphoma

Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin's Lymphoma

  • October 15, 2020
Innovent and Lilly's Halpryza (biosimilar- rituximab) Receive NMPA's Approval in China

Innovent and Lilly's Halpryza (biosimilar- rituximab) Receive NMPA's Approval in China

  • October 12, 2020
Cadila to Launch its Ritucad (rituximab- biosimilar) in India

Cadila to Launch its Ritucad (rituximab- biosimilar) in India

  • July 29, 2020
Sandoz Receives Health Canada's Approval to Launch Ziextenzo (biosimilar- pegfilgrastim) and Riximyo (biosimilar- rituximab) in Canada

Sandoz Receives Health Canada's Approval to Launch Ziextenzo (biosimilar- pegfilgrastim) and Riximyo (biosimilar- rituximab) in Ca...

  • June 10, 2020
Roche Highlights Data from the P-III (STARGLO) Trial of Columvi to Treat Diffuse Large B-Cell Lymphoma at EHA 2024

    Roche Highlights Data from the P-III (STARGLO) Trial of Columvi to Treat Diffuse Large B-Cell Lymphoma at EHA 2024

    • June 17, 2024
    BeiGene to Highlight Data from P-III (SEQUOIA) Study of Brukinsa in Combination with Venetoclax for CLL/SLL at EHA2024

      BeiGene to Highlight Data from P-III (SEQUOIA) Study of Brukinsa in Combination with Venetoclax for CLL/SLL at EHA2024

      • June 14, 2024
      Pfizer Reports the P-III (ECHELON-3) Trial Results of Adcetris for Treating R/R Diffuse Large B-cell Lymphoma (DLBCL)

        Pfizer Reports the P-III (ECHELON-3) Trial Results of Adcetris for Treating R/R Diffuse Large B-cell Lymphoma (DLBCL)

        • June 3, 2024
        AstraZeneca Reports Data from the P-III (ECHO) Study of Calquence Combination Regimen for Mantle Cell Lymphoma

          AstraZeneca Reports Data from the P-III (ECHO) Study of Calquence Combination Regimen for Mantle Cell Lymphoma

          • May 2, 2024
          Pfizer Reports P-III Study Results of Adcetris for Treating Diffuse Large B-cell Lymphoma (DLBCL)

            Pfizer Reports P-III Study Results of Adcetris for Treating Diffuse Large B-cell Lymphoma (DLBCL)

            • March 13, 2024
            BioInvent Signs a Clinical Supply Agreement with AstraZeneca to Assess BI-1206 for Treating Non-Hodgkin

              BioInvent Signs a Clinical Supply Agreement with AstraZeneca to Assess BI-1206 for Treating Non-Hodgkin's Lymphoma

              • February 9, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.